Trending...
- Melekel translates an inheritance from a distant past in new album titled Ancient Legacy
- Insure.com Names the Best Auto, Home, Life and Health Insurance Companies for 2023
- Justine Kelly Joins Jenny Craig as Executive Chef and Vice President of Culinary Strategy
SAN DIEGO--(BUSINESS WIRE)--Escient Pharmaceuticals, a clinical-stage company advancing novel small molecule therapeutics for the potential treatment of a broad range of neurosensory-inflammatory disorders, today announced the closing of a $120 million Series C financing.
The financing was co-led by NEA, Abingworth, and Forge Life Science Partners with participation from other new investors Avego, PFM Health Sciences, and The Eleven Fund, as well as the company's existing investors The Column Group, 5AM Ventures, Redmile Group, Cowen Healthcare Investments, Sanofi Ventures, Osage University Partners (OUP), and Altitude Life Science Ventures.
Proceeds from the financing will be used to advance the company's pipeline of two first-in-class product candidates in several indications. This includes clinical proof-of-concept studies for EP262 (MRGPRX2 antagonist) in chronic spontaneous urticaria (CSU), chronic inducible urticaria (CindU) and atopic dermatitis (AD) and for EP547 (MRGPRX4 antagonist) in cholestatic pruritus.
More on The Californer
Escient's initial focus is on a novel class of cell surface receptors called Mas-related G protein-coupled receptors, or MRGPRs. MRGPRs are chemosensory receptors expressed on sensory neurons and immune cells, which reside in close proximity to one another in key barrier tissues such as the skin, airways and gastrointestinal tract. MRGPRs mediate the neuro-immune overactivation that is a hallmark of numerous chronic disorders, including many allergic, inflammatory, auto-immune, pain and pruritic diseases.
"By specifically blocking the activation of MRGPRX2 and MRGPRX4 with small molecule antagonists, we aim to develop effective oral medications with novel mechanisms of action for serious neurosensory-inflammatory diseases without the serious side effects observed with other approaches," said Joshua Grass, Chief Executive Officer of Escient Pharmaceuticals. "We are thrilled with the support from both existing and new investors, and this significant financing puts us in a great position to advance our pipeline to clinical proof-of-concept in multiple indications."
More on The Californer
About Escient Pharmaceuticals
Escient Pharmaceuticals is a clinical-stage company focused on developing novel therapeutics to address a broad range of neurosensory-inflammatory disorders. The company's pipeline includes two first-in-class small molecule antagonists targeting MRGPRX2 for the treatment of various mast cell mediated disorders and MRGPRX4 for cholestatic pruritus. Based in San Diego, California, Escient is led by an experienced management and scientific team and funded by top-tier life science investors.
Visit www.escientpharma.com to learn more.
Contacts
Aaron Mishel
Chief Financial Officer
Escient Pharmaceuticals, Inc.
info@escientpharma.com
The financing was co-led by NEA, Abingworth, and Forge Life Science Partners with participation from other new investors Avego, PFM Health Sciences, and The Eleven Fund, as well as the company's existing investors The Column Group, 5AM Ventures, Redmile Group, Cowen Healthcare Investments, Sanofi Ventures, Osage University Partners (OUP), and Altitude Life Science Ventures.
Proceeds from the financing will be used to advance the company's pipeline of two first-in-class product candidates in several indications. This includes clinical proof-of-concept studies for EP262 (MRGPRX2 antagonist) in chronic spontaneous urticaria (CSU), chronic inducible urticaria (CindU) and atopic dermatitis (AD) and for EP547 (MRGPRX4 antagonist) in cholestatic pruritus.
More on The Californer
- Moorpark College to Launch Bachelor's Degree in Applied Biomanufacturing
- LA County Launches Fair Chance Hiring Program to Give System-Impacted Individuals an Equal Chance at Employment
- Workforce Development Board of Ventura County Invites Public Comments On Regional And Local Plans
- SUNCITY ADVISING Selected To Be A Part Of Google Ads Planning Advisory Council
- My Lineage Proudly Supports Knights of Heroes
Escient's initial focus is on a novel class of cell surface receptors called Mas-related G protein-coupled receptors, or MRGPRs. MRGPRs are chemosensory receptors expressed on sensory neurons and immune cells, which reside in close proximity to one another in key barrier tissues such as the skin, airways and gastrointestinal tract. MRGPRs mediate the neuro-immune overactivation that is a hallmark of numerous chronic disorders, including many allergic, inflammatory, auto-immune, pain and pruritic diseases.
"By specifically blocking the activation of MRGPRX2 and MRGPRX4 with small molecule antagonists, we aim to develop effective oral medications with novel mechanisms of action for serious neurosensory-inflammatory diseases without the serious side effects observed with other approaches," said Joshua Grass, Chief Executive Officer of Escient Pharmaceuticals. "We are thrilled with the support from both existing and new investors, and this significant financing puts us in a great position to advance our pipeline to clinical proof-of-concept in multiple indications."
More on The Californer
- Long Beach: City Announces Visual Improvement Grants Available for Small Businesses Impacted by Crime and Vandalism
- Kettering College Selects YuJa Enterprise Video Platform to Serve Students Pursuing Health Science Education
- $10,000 Grant From Palm Springs Women In Film & Television!s Filmmakers Lab And Stage 32
- 10 reasons why its intelligent to work with a Shopify partner to build Shopify Websites
- San Jose: Media Advisory: Council District 2 Kicks Off the New Year with Two Ribbon Cutting Ceremonies
About Escient Pharmaceuticals
Escient Pharmaceuticals is a clinical-stage company focused on developing novel therapeutics to address a broad range of neurosensory-inflammatory disorders. The company's pipeline includes two first-in-class small molecule antagonists targeting MRGPRX2 for the treatment of various mast cell mediated disorders and MRGPRX4 for cholestatic pruritus. Based in San Diego, California, Escient is led by an experienced management and scientific team and funded by top-tier life science investors.
Visit www.escientpharma.com to learn more.
Contacts
Aaron Mishel
Chief Financial Officer
Escient Pharmaceuticals, Inc.
info@escientpharma.com
Filed Under: Business
0 Comments
Latest on The Californer
- How we organized a meetup for DevOps engineers
- J:COM Deploys Qwilt's Open Caching Solution to Deliver Superior Digital Experiences Across Japan
- Pine Creek Care Center Responds to Verdict in Rios Suit; Defends Care Provided
- Nautilus Launches "Dr. Prune" Caffeinated Prune Juice
- Tin Mok Appointed to Faraday Future's Board of Directors as an Executive Director
- Abusive Russian to face Pro Wrestling Legend!
- Jim Wilson, Top Notch Realtor in waterfront and beach properties in Redington, Redington Shores, and North Redington Beach, FLorida
- DPFTRAC'S Diesel Particulate Filter (DPF) Cleaning Standards, Procedures, Compliance, EPA 's PM 2.5
- Multi #1 International Best-Selling Author Jennifer S. Wilkov Announces the 2023 April Speak Up Women Conference and Call For Speakers
- JARRARD INC. ADDS RENOWNED HEALTHCARE COMMUNICATIONS EXECUTIVE TO ROSTER
- Ventura College Foundation Provides $776,264 Direct Student Support During 2021-2022 Academic Year
- California: State Water Project to Increase Expected 2023 Deliveries
- RealDefense Acquires SUPERAntiSpyware From Support.com
- Creators Society Animation Podcast Launches Season 3 With An Interview With Kristine Belson, President Of Sony Pictures Animation
- The King of Urban Content Introduces EVERYWHERE Theater
- The Mogharebi Group Brokers $7.25 Million Sale of Costa Mesa, CA Multifamily Community
- San Jose: : San José Celebrates Over $62 Million in Grants for Transportation Safety
- Elden Ring, Stray, God of War Ragnarök, and Pentiment Lead Finalists for the 23rd Annual Game Developers Choice Awards
- Verb Presents Welcomes Josh Dean, Author of The Taking of K-129, The Most Daring Covert Operation in US History
- Bosco Tech Names Alumnus Adam Uballez Varsity Football Head Coach